Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Andrea Wang‐Gillam

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0458-7614; OpenAlex author ID A5008330168; NIH RePORTER profile ID 9837500. Sources: OpenAlex.

Their work

Papers
68 (first author 6, last author 14)
Trials
0
Grants
2
Labs led
1
Collaborators
255
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 8 papers · 2014: 3 papers · 2015: 5 papers · 2016: 8 papers · 2017: 7 papers · 2018: 5 papers · 2019: 6 papers · 2020: 4 papers, 1 grant · 2021: 3 papers · 2022: 2 papers · 2023: 6 papers · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper, 1 grant

Papers 50 of 68

  1. Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer. Co-author DOI 10.1126/sciadv.aei1190↗
  2. Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1821↗
  3. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. Co-author DOI 10.1016/j.gassur.2023.12.022↗
  4. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗
  5. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.013↗
  6. ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER… Co-author DOI 10.3389/fonc.2024.1339302↗
  7. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Co-author DOI 10.1001/jamanetworkopen.2022.49720↗
  8. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial. Co-author DOI 10.1016/j.ijrobp.2022.07.015↗
  9. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac237↗
  10. Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltrat… Co-author DOI 10.1158/1078-0432.ccr-23-0535↗
  11. A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy. Co-author DOI 10.1158/1078-0432.ccr-23-1405↗
  12. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Co-author DOI 10.1158/1078-0432.ccr-23-2993↗
  13. A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and be… Last author DOI 10.1002/cam4.4768↗
  14. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Co-author DOI 10.1158/1078-0432.ccr-22-0308↗
  15. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2020.7328↗
  16. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Co-author DOI 10.1016/j.adro.2020.06.010↗
  17. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. Co-author DOI 10.1200/po.20.00494↗
  18. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPO… Last author DOI 10.1097/mpa.0000000000001455↗
  19. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectabl… Co-author DOI 10.1097/sla.0000000000004155↗
  20. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1025↗
  21. Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Last author DOI 10.21037/jgo.2019.11.06↗
  22. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1002/cam4.2425↗
  23. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Co-author DOI 10.1016/j.ejca.2018.09.029↗
  24. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Co-author DOI 10.1016/j.ejca.2018.12.007↗
  25. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. Co-author DOI 10.1016/j.jgo.2019.02.011↗
  26. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  27. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  28. Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.031↗
  29. Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-1366↗
  30. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Co-author DOI 10.1158/1535-7163.mct-17-1142↗
  31. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancrea… Co-author DOI 10.1200/jco.2017.74.9564↗
  32. Dynamic changes during the treatment of pancreatic cancer. First author DOI 10.18632/oncotarget.24483↗
  33. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomize… Co-author DOI 10.1001/jamaoncol.2016.5383↗
  34. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based … Co-author DOI 10.1038/bjc.2017.67↗
  35. Digital Ischemia and Necrosis: A Rarely Described Complication of Gemcitabine in Pancreatic Adenocarcinoma. Last author DOI 10.1089/pancan.2017.0012↗
  36. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-16-1121↗
  37. Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. Co-author DOI 10.1200/jco.2016.70.1607↗
  38. A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.15653↗
  39. Trends in Neoadjuvant Approaches in Pancreatic Cancer. First author DOI 10.6004/jnccn.2017.0134↗
  40. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Co-author DOI 10.1016/j.ccell.2015.11.011↗
  41. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  42. Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply. First author DOI 10.1016/s0140-6736(16)30365-8↗
  43. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… First author DOI 10.1016/s1470-2045(16)00078-4↗
  44. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  45. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Last author DOI 10.1080/14737140.2016.1174581↗
  46. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pa… Co-author DOI 10.1097/coc.0000000000000003↗
  47. Racial Disparities in the Outcomes of Patients With Stage IV Pancreatic Adenocarcinoma Are Mediated by Chemotherapy Utilization. Co-author DOI 10.1097/mpa.0000000000000618↗
  48. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Co-author DOI 10.1007/s10637-015-0246-2↗
  49. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.hoc.2015.04.011↗
  50. Natural history of preoperative subcentimeter pulmonary nodules in patients with resectable pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/sla.0000000000000719↗

Grants 2

  1. Research Project 2 U54CA224083↗
  2. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗

Closest collaborators

The 25 strongest of 255 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kian‐Huat Lim · 17 shared papers, 1 shared grant, 2012–2026 · strength 2.88
  2. William G. Hawkins · 15 shared papers, 1 shared grant, 2011–2026 · strength 1.46
  3. David G DeNardo · 11 shared papers, 1 shared grant, 2013–2025 · strength 1.12
  4. Katrina Sophia Pedersen · 8 shared papers, 2015–2025 · strength 1.05
  5. Cynthia X Ma · 1 shared grant, 2026 · strength 1.00
  6. Ryan C Fields · 7 shared papers, 1 shared grant, 2013–2024 · strength 0.85
  7. Patrick M. Grierson · 6 shared papers, 2018–2025 · strength 0.84
  8. Albert Craig Lockhart · 9 shared papers, 1 shared grant, 2012–2023 · strength 0.84
  9. Philip A. Philip · 6 shared papers, 2017–2024 · strength 0.78
  10. Muhammad Shaalan Beg · 5 shared papers, 2020–2024 · strength 0.73
  11. Andrew M. Lowy · 6 shared papers, 2013–2024 · strength 0.67
  12. Davendra P. S. Sohal · 5 shared papers, 2019–2024 · strength 0.65
  13. Li‐Tzong Chen · 7 shared papers, 2016–2020 · strength 0.60
  14. Feng Gao · 7 shared papers, 2011–2026 · strength 0.58
  15. Elena Gabriela Chiorean · 4 shared papers, 2020–2024 · strength 0.58
  16. Jens Thomas Siveke · 6 shared papers, 2017–2020 · strength 0.53
  17. William E. Gillanders · 2 shared papers, 1 shared grant, 2011–2026 · strength 0.47
  18. Bruce Belanger · 5 shared papers, 2016–2020 · strength 0.44
  19. David C. Linehan · 12 shared papers, 2011–2016 · strength 0.44
  20. Elizabeth M. Jaffee · 5 shared papers, 2014–2026 · strength 0.42
  21. Vincent J. Picozzi · 6 shared papers, 2013–2022 · strength 0.40
  22. Daniel D. Von Hoff · 5 shared papers, 2016–2019 · strength 0.40
  23. Jean‐Frédéric Blanc · 4 shared papers, 2017–2020 · strength 0.35
  24. Floris A. de Jong · 4 shared papers, 2017–2019 · strength 0.35
  25. Dominic E. Sanford · 5 shared papers, 2013–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.